[HARTMANN, Rolf, FROTSCHER, Martin, OBERWINKLER, Sandrine, ZIEGLER, Erika, MESSINGER, Josef, THOLE, Heinrich-Hubert] DE,66123 Saarbrücken,Campus Saarbrücken;

[MESSINGER, Josef, THOLE, Heinrich-Hubert, RASCHE, Heinz-Helmer, SCHMIDT, Michael, HAKALA, Juha] DE,30173 Hannover,Hans-Böckler-Allee 20;

[HIRVELÄ, Leena, HUSEN, Bettina, KIVINIEMI, Johanna, KOSKIMIES, Pasi, LEHTOVUORI, Pekka, MESSINGER, Josef, PENTIKÄINEN, Olli Taneli, PIRKKALA, Lila, SAARENKETO, Pauli, THOLE, Heinrich-Hubert, UNKILA, Mikko, VAN STEEN, Bartholomeus Johannes] DE,30173 Hannover,Hans-Böckler-Allee 20;

[MESSINGER JOSEF, THOLE HEINRICH-HUBERT, HUSEN BETTINA, VAN STEEN BARTHOLOMEUS JOHANNES, SCHNEIDER GYULA, HULSHOF JOHANNES BERNARDUS EVERARDUS, KOSKIMIES PASI, JOHANSSON NINA, ADAMSKI JERZY] DE The present invention relates to novel 3, 15 substituted estrone derivatives which represent inhibitory compounds of the 17(-hydroxysteroid dehydrogenase type I (17(-HSD1), to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel 3, 15 substituted estrone derivatives, particularly their use in the treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17(-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17(-estradiol concentration. In addition, the present invention relates to the general use of selective 17(-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment and prevention of benign gynaecological disorders, in particular endometriosis.

[HIRVELAE LEENA, HUSEN BETTINA, KIVINIEMI JOHANNA, KOSKIMIES PASI, LEHTOVUORI PEKKA, MESSINGER JOSEF, PENTIKAEINEN OLLI TANELI, KALLIO LILA, SAARENKETO PAULI, THOLE HEINRICH-HUBERT, UNKILA MIKKO, VAN STEEN BARTHOLOMEUS JOHANNES] DE This invention relates to novel substituted thiophenepyrimidinone derivatives and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorder, such as steroid hormone dependent diseases or disorders requiring inhibition of 17ß-hydroxysteroid dehydrogenase enzymes.

[THOLE HEINRICH-HUBERT, KOSKIMIES PASI, SCHNEIDER GYULA, JOHANSSON NINA, HUSEN BETTINA, STEEN BARTHOLOMEUS JOHANNES VAN, ADAMSKI JERZY, HULSHOF JOHANNES BERNARDUS EVERARDUS, MESSINGER JOSEF] DE

[Josef Messinger, Christiane Boecker, Heinrich-Hubert Thole, Bettina Husen, Maria Hinaje, Monika Buchholz] DE,,Sehnde;DE,,Hannover;DE,,Hannover;DE,,Hannover;FR,,Nancy;DE,,Langenfeld; Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy.

[Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Lila Kallio nee Pirkkala] DE,,Sehnde;DE,,Burgdorf;DE,,Hannover;DE,,Hannover;FI,,Turku;FI,,Kaarina; Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.

[Josef MESSINGER, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Mikko Unkila] DE,,Sehnde;DE,,Burgdorf;DE,,Hannover;DE,,Hannover;FI,,Turku;FI,,Kaarina; Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.

[KOSKIMIES PASI, WESKE MICHAEL, MESSINGER JOSEF, THOLE HEINRICH-HUBERT, HUSEN BETTINA, PIRKKALA LILA] DE The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17????-hydroxysteroid dehydrogenase type I (17????-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17????-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17????-estradiol concentration.